Mice lacking MSK1 and MSK2 show reduced skin tumor development in a two-stage chemical carcinogenesis model

Simon Chang1, Lars Iversen, Knud Kragballe

  • 1Department of Dermatology, Aarhus University Hospital, Denmark.

Cancer Investigation
|February 15, 2011
PubMed
Abstract

Insights

Mitogen- and stress-activated protein kinase (MSK)1/2 signaling promotes skin tumor development. MSK1/2 knockout mice showed fewer tumors but increased inflammation markers, suggesting a complex role in skin carcinogenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Mitogen- and stress-activated protein kinase (MSK)1/2 are kinases implicated in inflammatory responses and cellular transformation.
  • Understanding the precise role of MSK1/2 in carcinogenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the in vivo role of MSK1/2 in the development of skin tumors.
  • To elucidate the molecular mechanisms underlying MSK1/2 involvement in skin carcinogenesis.

Main Methods:

  • Utilized MSK1/2 knockout mice and wild-type littermates for comparative studies.
  • Assessed skin tumor development following chemical induction (TPA).
  • Quantified myeloperoxidase activity and measured mRNA and protein levels of key inflammatory cytokines (IL-1β, TNF-α).

Main Results:

  • MSK1/2 knockout mice exhibited a significant reduction in skin tumor formation compared to wild-type controls.
  • Elevated myeloperoxidase activity was observed in the skin of TPA-treated MSK1/2 knockout mice.
  • Increased mRNA and protein levels of IL-1β, and elevated mRNA expression of TNF-α were noted in MSK1/2 knockout mice.

Conclusions:

  • MSK1/2 signaling acts as a novel tumor-promoting axis in skin carcinogenesis.
  • These findings highlight MSK1/2 as a potential therapeutic target for preventing or treating skin cancer.
  • The study underscores the complex interplay between inflammation and tumor promotion mediated by MSK1/2.